Table 1.
Baseline characteristics.
| No.(%) | ||
|---|---|---|
| FOLFIRI (n = 88) | IRI (n = 84) | |
| Age (years) | ||
| <65 | 59 (67) | 52 (62) |
| ⩾65 | 29 (33) | 32 (38) |
| Median (IQR) | 59 (50–66) | 61 (53–68) |
| Sex | ||
| Men | 52 (59) | 54 (64) |
| Women | 36 (41) | 30 (36) |
| ECOG performance status a | ||
| 0–1 | 86 (98) | 83 (99) |
| 2 | 2 (2) | 1 (1) |
| Stage at diagnosis | ||
| Synchronous metastasis | 56 (64) | 54 (64) |
| Metachronous metastasis | 32 (36) | 30 (36) |
| Primary tumor location | ||
| Right side | 27 (31) | 21 (25) |
| Left side | 61 (69) | 63 (75) |
| Primary tumor resection | ||
| Yes | 64 (73) | 54 (64) |
| No | 24 (27) | 30 (36) |
| Pathological type | ||
| Adenocarcinoma | 73 (83) | 73 (87) |
| Mucinous adenocarcinoma/signet ring | 15 (17) | 11 (13) |
| Number of metastatic sites | ||
| 1–2 | 50 (57) | 46 (55) |
| >2 | 38 (43) | 38 (45) |
| Liver metastases | ||
| Yes | 57 (65) | 56 (67) |
| No | 31 (35) | 28 (33) |
| Liver-limited metastases | ||
| Yes | 21 (24) | 20 (24) |
| No | 67 (76) | 64 (76) |
| UGT1A1 polymorphism | ||
| Wild | 37 (42) | 36 (43) |
| Single heterozygote | 26 (30) | 31 (37) |
| Double heterozygotes or homozygotes | 8 (9) | 5 (6) |
| Unknown | 17 (19) | 12 (14) |
| K-RAS and N-RAS status | ||
| Wild | 43 (49) | 32 (38) |
| Mutant | 36 (41) | 34 (41) |
| Unknown | 9 (10) | 18 (21) |
| BRAF status | ||
| Wild | 75 (85) | 63 (75) |
| Mutant | 4 (5) | 3 (4) |
| Unknown | 9 (10) | 18 (21) |
ECOG, Eastern Cooperative Oncology Group; FOLFIRI, folinic acid, fluorouracil, and irinotecan; IRI, irinotecan.
Data are n (%) or median (IQR).
a
Assessed according to ECOG guidelines.